Cost-Effectiveness of Dexamethasone Intravitreal Implant in Naïve and Previously Treated Patients with Diabetic Macular Edema.

Marta Medina-BaenaOlga Cejudo-CorbalánFernando Labella-QuesadaEloy Girela-López

Published in: International journal of environmental research and public health (2023)

DEX-i was found to be more cost-effective in treatment-naïve eyes than in those previously treated with anti-VEGF. Further studies are needed to determine the most cost-effective treatment based on patient profile.

Keyphrases

vascular endothelial growth factor
low dose
endothelial cells
combination therapy
diabetic retinopathy
soft tissue
case control
case report